The Global Immune–Nutrition–Inflammation Index (GINI) as a Candidate Prognostic Marker in Patients with Cutaneous Squamous Cell Carcinoma Treated with Cemiplimab
Tara Coreanu, Ido Amir, Nofar Edri, Itamar Averbuch, Aviram Mizrachi, Amit Ritter, Moran Amit, Noga Kurman, Eyal Yosefof, Dan Yaniv · 2026
Read The Global Immune–Nutrition–Inflammation Index (GINI) as a Candidate Prognostic Marker in Patients with Cutaneous Squamous Cell Carcinoma Treated with Cemiplimab by Tara Coreanu, Ido Amir, Nofar Edri, Itamar Averbuch, Aviram Mizrachi, Amit Ritter, Moran Amit, Noga Kurman, Eyal Yosefof, Dan Yaniv (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565106.txt.
Description
Tara Coreanu and nine colleagues published a 2026 study on a blood score that may foretell outcomes in skin cancer care. The cancer is cutaneous squamous cell carcinoma, a common skin malignancy. A drug called cemiplimab has changed its treatment, but doctors lack a good test to sort patients by risk before therapy.
Their score, called GINI, blends immune strength, nutrition, and inflammation into one number. The team checked whether the score, taken before treatment, tracks how patients fare on the drug. Patients across all disease stages were included. A cheap blood-based score could help teams choose who needs closer watch or stronger care. The study tests GINI as that sorting tool.
Catalog record
| CREATOR | Tara Coreanu, Ido Amir, Nofar Edri, Itamar Averbuch, Aviram Mizrachi, Amit Ritter, Moran Amit, Noga Kurman, Eyal Yosefof, Dan Yaniv |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |